Patients ( n = 214 ) with active RA ( 6 swollen and tender joints , C-reactive protein 10 mg/L ) on oral DMARDs were randomized ( 2:2:1 ) to receive pateclizumab 360 mg , adalimumab 40 mg , or placebo subcutaneously every 2 weeks .